92results about "Phosphorus-oxygen lyases" patented technology

In alternative embodiments, the invention provides phosphatidylinositol-specific phospholipase C (PI-PLC) enzymes, nucleic acids encoding them, antibodies that bind specifically to them, and methods for making and using them. Industrial methods and products comprising use of these phospholipases are also provided. In certain embodiments, provided herein are methods for hydration of non hydratable phospholipids (NHPs) within a lipid matrix. The methods enable migration of NHPs to an oil-water interface thereby allowing the NHPs to be reacted and/or removed from the lipids. In certain embodiments, provided is a method for removing NHPs, hydratable phospholipids, and lecithins from vegetable oils to produce a degummed oil or fat product that can be used for food production and/or non-food applications. In certain embodiments, provided herein are methods for hydration of NHPs followed by enzymatic treatment and removal of various phospholipids and lecithins. The methods provided herein can be practiced on either crude or water-degummed oils.

The present invention is directed generally to eukaryotic host cells comprising artificial endosymbionts and methods of introducing artificial endosymbionts into eukaryotic host cells. The invention provides artificial endosymbionts that introduce a phenotype to host cells that is maintained in daughter cells. The invention additionally provides eukaryotic host cells containing magnetotactic bacteria.

Terpenes are valuable commercial products used in a diverse number of industries. Terpenes may be produced from petrochemical sources and from terpene feed-stocks, such as turpentine. However, these production methods are expensive, unsustainable and often cause environmental problems including contributing to climate change. Microbial fermentation provides an alternative option for the production of terpenes. One or more terpenes and/or precursors can be produced by microbial fermentation of a substrate comprising CO. Recombinant microorganisms may be used in such methods. Carboxydotrophic, acetogenic, recombinant microorganisms can be used in such methods. The recombinant microorgnsims may contain exogenous mevalonate (MVA) pathway enzymes and/or DXS pathway enzymes, for example.

The methods and apparatus of the present invention allow the evaluation of inflammation of the esophagus. Measurements may be utilized, for example, to diagnose a disease of the esophagus, to monitor inflammation of the esophagus, or to access the treatment of a disease of the esophagus. In one embodiment, the invention comprises a method for measuring esophageal inflammation comprising deploying a device into the esophagus of a subject, removing the device after a predetermined period of time, analyzing the device for a diagnostic indicator of esophageal inflammation and evaluating the diagnostic indicator to diagnose esophageal inflammation.

An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.

The present disclosure provides compositions and methods for biologically producing isoprene using methanotrophic bacteria that utilize carbon feedstock, such as methane or natural gas.

The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.

The invention discloses a method for preparing cyclic adenosine monophosphate by adenylate cyclase. The method comprises the following steps that the adenylate cyclase serves as a catalyst, adenosinetriphosphate serves as a substrate, and in the presence of Mg <2+>, a reaction solution containing the cyclic adenosine monophosphate is obtained. According to the adenylate cyclase, an amino acid sequence as shown in SEQ ID NO.14 is provided, the stability is good, the half-life period is long at medium and low temperatures, ATP can be efficiently catalyzed to generate cAMP in one step at mediumtemperature, a substrate conversion rate reaches 90 % or above, the advantages of simple industry, mild conditions, short period, few by-products and the like are achieved, the clean and pollution-free effects are achieved, and the energy conservation, consumption reduction and emission reduction in the cAMP production process can be realized.

The invention discloses a polypeptide for recognizing immune cells. The polypeptide comprises the following amino acid sequences: (a) an amino acid sequence of a C-terminal fragment sequence EQPDPGAVAAAAILRAILE containing human Triokinase/FMN cyclase; or (b) an amino acid sequence which is basically the same as the amino acid sequence in (a), and the basically the same means that the amino acid sequence in (a) has more than 80% of identity with that in (b). The invention also discloses a nucleic acid sequence for encoding the polypeptide; the polypeptide for targeted recognition of immune cells comprising the polypeptide and a polypeptide probe with a reporter group; a kit comprising the probe; and an application of the polypeptide or the probe in preparation of the kit for imaging livingcells of mammals.

The present invention provides machine readable media embedded with the three-dimensional molecular structure coordinates of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase, and subsets thereof, including binding pockets, methods of using the structure to identify and design affecters, including inhibitors and activator, mutants of MECPS, and compounds and compositions that affect MECPS activity.

The present invention provides materials and methods useful to treat various sGCα1-expressing cancers. Materials include peptides which interfere with sGCα1's pro-survival functions, thereby resulting in apoptosis of sGCα1-expressing cells. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits.

The invention provides methods for treating, ameliorating or protecting (preventing) an individual or a patient having or at risk of having heart disease or heart failure, or decreased cardiac function, comprising: providing a cyclic adenosine monophosphate-incompetent (cAMP-incompetent) adenylyl cyclase type 6 (AC6) protein or polypeptide (also called "an AC6mut"), or an AC6mut -encoding nucleic acid or a gene operatively linked to a transcriptional regulatory sequence.

The present invention lies in the field of molecular biology, recombinant peptide and protein expression and relates to methods comprising nucleic acid sequences comprising allocrites of T1SSs or fragments thereof for the efficient production of recombinant Pe OIs and Pr OI. The allocrites or fragments thereof improve the expression of PeOI and Pr OI as IB and function as IB-tags.

An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.

The invention discloses an improved preparation method of adenylate cyclase. The preparation method comprises the following steps: (1) optimizing a codon of a to-be-expressed gene; (2) carrying out PCR reaction on a target fragment; (3) purifying and recycling a PCR product; (4) constructing a recombinant expression carrier; and (5) carrying out cell-free protein synthesis reaction on a target gene. The preparation method disclosed by the invention has the advantages that molecular biology and genetic engineering methods are adopted, the recombinant expression carrier of an adenylate cyclase gene is constructed, and expression is induced, so that a recombinant protein is obtained.

The invention discloses target cell specificity fusion protein serving as a porcine reproductive and respiratory syndrome viral vaccine antigen and a vaccine composition. The target cell specificity fusion protein is composed of an amino acid sequence of adenylate cyclase of bordetella lack of an N-terminal enzymatic structural domain and amino acid sequences of the antigen, wherein the amino acid sequences of the antigen comprise the nucleoprotein partial sequence of the porcine reproductive and respiratory syndrome viruses, the partial sequence of membrane protein (M protein) and the partial sequence of M protein GP5. The amino acid sequences of the antigen are located at the N-terminal of the amino acid sequence of adenylate cyclase of bordetella lack of the N-terminal enzymatic structural domain. The fusion protein can successfully induce cellular immune responses and antibody production of animal bodies, can perform a huge effect in the field of producing vaccines by applying medicine compositions composed of BPAC-CM5RM5 fusion protein and carriers or adjuvant in future, and can further prevent porcine reproductive and respiratory syndromes from happening.

The invention discloses a preparation method of purified coupling immobilized adenylate cyclase. The preparation method comprises the following steps: (1) preparing an affinity adsorption medium: adding 5-100g of a metal chelating resin carrier with surface modified by iminodiacetic acid to 10-200mL of 0.01-1mol/L of an NiCl2.6H2O solution, conducting oscillating at 25-30 DEG C and under 150-200rpm for 2-4h, and conducting filtration, so that the affinity adsorption medium is obtained; (2) immobilizing enzyme: adding 1.5-15ml of an adenylate cyclase solution which is 0.1-2mg/mL in concentration to 0.1-1g of the affinity adsorption medium obtained in the step (1), conducting oscillating at 25-30 DEG C and under 150-200rpm for 2-4h, and conducting centrifuging, so that the immobilized adenylate cyclase is obtained, wherein the adenylate cyclase is provided with a histidine tag. The immobilized enzyme prepared by the invention has the advantages of being high in enzymatic activity, low in enzymatic activity loss and the like, and the immobilized enzyme can be repeatedly used.